Northshore Hamilton Welcomes First Needle-Free Vaccine Patch Facility In Australia

Needle-Free Vaccine Patch Vaxxas
Photo Credit: BrisbaneCityCouncil

Did you know that Northshore Hamilton now has a state-of-the-art biomedical manufacturing facility producing Australia’s first needle-free vaccine patch?

Queensland biotechnology company Vaxxas plans to manufacture millions of needle-free vaccines at the new facility where cutting-edge technology produces patches that allow vaccines to be administered through the skin’s surface in a matter of seconds. This breakthrough innovation positions Queensland as a leading player in the globally competitive Asia-Pacific biomedical industry.

The facility is expected to boost the state’s economy and create up to 200 local and skilled jobs. The State Government provided funding and operational support to Vaxxas, aiding the transformation of an existing warehouse at Northshore into the manufacturing facility. 

With completed human clinical trials and ongoing studies for COVID-19, influenza, and other vaccine targets, Vaxxas’ needle-free vaccine patch technology is progressing rapidly toward commercialization. David Hoey, Vaxxas CEO, expects the first commercially available vaccine patches to be manufactured and distributed from the Queensland facility within the next three to five years.

Photo Credit: Vaxxas

The government’s commitment to supporting local biomedical start-ups and fostering innovation has contributed to Queensland’s growing reputation as a research and innovation hub.

Tower Ad

The establishment of the Vaxxas facility aligns with the Queensland Government’s Biomedical 10-Year Roadmap and Action Plan, which aims to further develop the biomedical sector in the state. Currently contributing $2.1 billion to Queensland’s economy and employing over 12,000 people, the biomedical industry is set to attract more interstate and international businesses through the upcoming Queensland Biomedical Business Attraction Program.

Gino's Italian Restaurant

Deputy Premier Steve Miles expressed his excitement about the facility’s opening on 19 June 2023 and highlighted the importance of expanding Queensland’s capability in vaccine development, manufacturing, and delivery. He emphasized the vital role that Vaxxas’ needle-free technology could play in pandemic preparedness by enabling the quick and easy deployment of vaccines to communities.

Published 20-June-2023